

CA Tumor Markers 2017-2021: CA 15-3/27.29, CA 19-9, CA 125--US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review

<https://marketpublishers.com/r/CA0323D7FE3EN.html>

Date: December 2016

Pages: 278

Price: US\$ 4,360.00 (Single User License)

ID: CA0323D7FE3EN

Abstracts

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

This report presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 278 pages and 40 tables

Contents

I. INTRODUCTION

II. CA TUMOR MARKERS WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. CA Tumor Markers: Clinical Significance and Laboratory Practices

1. CA 15-3/27.29
2. CA 19-9
3. CA

B. Instrumentation Review And Market Needs

1. Abbott AxSYM
2. Abbott Architect c4000
3. Abbott Architect i2000 Series
4. Abbott Architect ci8200 System
5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP600
8. bioMerieux Mini Vidas
9. Carolina Chemistries BioLis 24i
10. DiaSorin Liaison
11. Horiba ABX Pentra
12. Inverness DS2
13. J&J Vitros ECi/ECiQ
14. J&J Vitros 3600
15. J&J Vitros 5600
16. Olympus AU5400
17. Olympus AU3000i
18. Olympus AU2700
19. Roche Modular Analytics
20. Roche Cobas Integra
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista
28. Siemens Immulite

- 29. Siemens Stratus
- 30. Tosoh AIA-Series
- 31. Vital Diagnostics ATAC 8000
- 32. Vital Diagnostics Envoy

C. Current and Emerging Technologies

- 1. Monoclonal and Polyclonal Antibodies
- 2. Immunoassays
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)
 - Overview
 - ELISA
 - Immunofiltration
 - Particle-Membrane Capture Immunoassay
 - Enzyme Amplification
 - d. Fluorescent Immunoassays
 - e. Luminescence
 - Chemiluminescence
 - Bioluminescence
 - f. Latex Agglutination
 - g. Immunoprecipitation
 - h. Affinity Chromatography
 - e. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
 - a. Technology Overview
 - b. Amplification Methods
 - PCR
 - DAP-PCR
 - Immuno-PCR
 - QC-PCR
 - CAR
 - DNA
 - HPA
 - LCR
 - NASBA
 - QBR
 - SDA
 - 3 SR, and others
- 4. Chromosome Analysis

- a. Chronic Myelogenous Leukemia (CML)
- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant Lymphomas
Lymphoid Malignancies
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
 - a. CT
 - b. MRI
 - c. NMR
 - d. PET
 - e. Photonics Spectroscopy
- E. Personal Testing

III. FRANCE: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES

IV. GERMANY: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES

V. ITALY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

VI. JAPAN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES

VII. SPAIN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES

VIII. U.K.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

IX. U.S.A.: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND

MARKET SHARES

X. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XI. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

XII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

XIII. COMPETITIVE PROFILES

Abbott
AdnaGen
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad

Cepheid
Correlogic Systems
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Hologic/Gen-Probe
Guided Therapeutics
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Thermo Fisher
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE

Zila

List Of Tables

LIST OF TABLES

Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
France CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
France CA 19-9 Test Volume and Diagnostics Sales by Market Segment
France CA 125 Test Volume and Diagnostics Sales by Market Segment
France CA 15-3/27.29 Testing Market by Major Supplier
France CA 19-9 Testing Market by Major Supplier
France CA 125 Testing Market by Major Supplier
Germany CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Germany CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Germany CA 125 Test Volume and Diagnostics Sales by Market Segment
Germany CA 15-3/27.29 Testing Market by Major Supplier
Germany CA 19-9 Testing Market by Major Supplier
Germany CA 125 Testing Market by Major Supplier
Italy CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Italy CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Italy CA 125 Test Volume and Diagnostics Sales by Market Segment
Japan CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Japan CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Japan CA 125 Test Volume and Diagnostics Sales by Market Segment
Japan CA 15-3/27.29 Testing Market by Major Supplier
Japan CA 19-9 Testing Market by Major Supplier
Japan CA 125 Testing Market by Major Supplier
Spain CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Spain CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Spain CA 125 Test Volume and Diagnostics Sales by Market Segment
Spain CA 15-3/27.29 Testing Market by Major Supplier
Spain CA 19-9 Testing Market by Major Supplier
Spain CA 125 Testing Market by Major Supplier
U.K. CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
U.K. CA 19-9 Test Volume and Diagnostics Sales by Market Segment
U.K. CA 125 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 19-9 Test Volume and Diagnostics Sales by Market Segment

U.S.A. CA 125 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 15-3/27.29 Testing Market by Major Supplier
U.S.A. CA 19-9 Testing Market by Major Supplier
U.S.A. CA 125 Testing Market by Major Supplier

I would like to order

Product name: CA Tumor Markers 2017-2021: CA 15-3/27.29, CA 19-9, CA 125--US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review

Product link: <https://marketpublishers.com/r/CA0323D7FE3EN.html>

Price: US\$ 4,360.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA0323D7FE3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970